About this trial
Chloroprocaine is a short-acting local anesthetic that allows rapid recovery and early ambulation but is currently recommended for procedures lasting 40 minutes or less.
Dexamethasone is commonly used during anesthesia for the prevention of postoperative nausea and vomiting and has also been shown to prolong the duration of analgesia and sensory block after regional anesthesia.
Dexamethasone may therefore extend the duration of chloroprocaine spinal anesthesia, potentially allowing its use for longer surgical procedures while maintaining the benefits of rapid postoperative recovery.
This study aims to evaluate whether intravenous dexamethasone can prolong the effects of spinal anesthesia performed with chloroprocaine in adults undergoing knee arthroscopy.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Undergoing knee arthroscopy lasting ≤ 40 minutes requiring spinal anesthesia (diagnostic arthroscopy or meniscal surgery),
Signed written informed consent form,
Affiliation to a social security system,
Negative pregnancy test on the day of procedure for non-menopausal patients.
Disqualifiers
Contraindications to spinal anesthesia with intrathecal chloroprocaine
History of diabetes,
Pre-existing peripheral neuropathy,
American Society of Anesthesiologists (ASA) physical status IV,
Trial design
Parallel
Treatments tested in this trial
Sodium Chloride 0.9%
DrugIV infusion of 3 mL of normal saline solution diluted in 100 mL of 0.9% sodium chloride, administered over 20 minutes
Dexamethasone
DrugIV infusion of dexamethasone at a dose of 0.15 mg/kg (maximum 16 mg), diluted in 100 mL of 0.9% sodium chloride, administered over 20 minutes
Chloroprocaine Injection [Clorotekal]
DrugSpinal anesthesia with chloroprocaine 40 mg
Treatment groups
Trial outcomes
Primary outcomes
Time to regression of sensory block by two dermatomes (pin-prick test)
Time (in minutes) from the spinal puncture to the first assessment at which the sensory block has regressed by two dermatomes from the maximum (highest/most cephalad) dermatome level of sensory block achieved after the puncture, assessed with the pin-prick test. Sensory testing will be performed every 5 minutes until two-dermatome regression is observed. Responses will be recorded as: 2 = sharp (normal sensation), 1 = dull (decreased sensation), and 0 = absent sensation.
Secondary outcomes
Time to complete resolution of motor block
Time (in minutes) from the spinal puncture to complete recovery of motor block, assessed by the Modified Bromage Scale (0-3: 0 = full flexion of hip, knee, and ankle; 1 = inability to raise extended leg; 2 = inability to flex knee; 3 = no movement of hip, knee, or ankle). Motor block will be assessed every 5 minutes after the spinal puncture until regression of the sensory block by two dermatomes, and then every 10 minutes until complete motor recovery (Bromage 0).
Time to regression of sensory block by four dermatomes (pin-prick test)
Time (in minutes) from the spinal puncture to regression of four dermatomes from the highest dermatome level of sensory block achieved after the puncture. Sensory block will be assessed using the pin-prick test every 5 minutes after the spinal puncture until regression by two dermatomes, and then every 10 minutes until regression by four dermatomes. Responses will be recorded as: 2 = sharp (normal sensation), 1 = dull (decreased sensation), and 0 = absent sensation.
Maximum sensory block level
Highest dermatome level of sensory block achieved after the spinal puncture (pin-prick test).
Time to maximum sensory block level
Time (in minutes) from the spinal puncture to the highest blocked dermatome (pin-prick test).
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: